Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects
Published . Updated .
The pharma giant is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes.
Directly affected
- PPLI People
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Price since this story was published: Acadia Healthcare (ACHC)
Since the first closing price after “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects,” Acadia Healthcare (ACHC) is +12.10%. The S&P 500 fund (SPY) is +0.33% over the same days, a +11.77% difference versus the market.
Disclosure records for Acadia Healthcare (ACHC) within two months of 30 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 1 days before publication, inside 30 days. The filing is listed beside the story “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 19 days before publication, inside 30 days. The filing is listed beside the story “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 58 days before publication, inside 60 days. The filing is listed beside the story “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies tied to this story
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
Acadia Healthcare (ACHC) is the company in “Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects,” the 30 Sep 2026 this story story.
The link for Acadia Healthcare (ACHC) is this: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Ascendis Pharma A/S (ASND), is listed for a different reason: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Acadia Healthcare (ACHC)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
What the saved facts support for Acadia Healthcare (ACHC)
100 out of 100
“Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects” scores 100 out of 100. The score uses 6 linked companies.